387 results
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
(i) Material Changes; Undisclosed Events
424B5
SEEL
Seelos Therapeutics Inc
20 May 24
Prospectus supplement for primary offering
4:16pm
, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December 31 … and auditing. The audit report covering the December 31, 2022 consolidated financial statements contains an explanatory paragraph that states
424B3
lv39r 61ny6o5tu162c
15 Mar 24
Prospectus supplement
4:15pm
8-K
EX-10.1
p06bxl jzdy4zlin
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
424B5
knvhd 79pvqfg9
30 Jan 24
Prospectus supplement for primary offering
6:05am
8-K
EX-1.1
x1j0rtz
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
424B5
3det3frk sr
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
jlgqb2h9tw975f cn
28 Nov 23
Prospectus supplement for primary offering
4:06pm